NovoCure (NVCR) EPS (Basic) (2014 - 2026)

NovoCure (NVCR) posted EPS (Basic) of -$0.13 for Q2 2026, up 78.34% sequentially from -$0.62 in Q1 2026, and up 62.48% YoY from -$0.08 in Q2 2025.

NovoCure (NVCR) EPS (Basic) (2014 - 2026) Analysis & Trends

NovoCure has reported EPS (Basic) for 13 years, with the latest figure at -$0.13 in Q2 2026.

Quarterly EPS (Basic) rose 62.48% year-over-year to -$0.13 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.28 (up 16.42% YoY) and the FY2025 annual result came in at -$1.22, up 21.85% from the prior year.
EPS (Basic) advanced to -$0.13 in Q2 2026 per NVCR's latest filing, from -$0.62 in the prior quarter.
Over five years, EPS (Basic) peaked at -$0.04 in Q1 2022 and troughed at -$0.62 in Q1 2026.
A 5-year average of -$0.35 and a median of -$0.34 in 2025 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2023 and 2025: EPS (Basic) sank 1025.83% in 2023, then jumped 64.05% in 2025.
Over 5 years, EPS (Basic) stood at -$0.36 in 2022, then decreased by 24.15% to -$0.44 in 2023, then plunged by 38.15% to -$0.61 in 2024, then surged by 64.05% to -$0.22 in 2025, then jumped by 38.59% to -$0.13 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.13, -$0.62, and -$0.22 for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Abbott Laboratories	200.19 Bn	194.59 Bn	7.27 Bn	0.53
2	Stryker	129.95 Bn	126.47 Bn	4.50 Bn	3.33
3	Medtronic	120.06 Bn	110.84 Bn	6.41 Bn	0.98
4	Boston Scientific	74.14 Bn	73.60 Bn	3.85 Bn	0.62
5	Edwards Lifesciences	52.74 Bn	48.49 Bn	1.35 Bn	0.42
6	Dexcom	34.60 Bn	32.65 Bn	830.00 Mn	0.65
7	GE HealthCare Technologies	34.20 Bn	32.10 Bn	2.18 Bn	1.27
8	Koninklijke Philips	26.46 Bn	23.13 Bn	4.55 Bn	0.65
9	Steris	23.25 Bn	22.77 Bn	684.20 Mn	2.06
10	NovoCure	2.06 Bn	1.62 Bn	142.48 Mn	-0.13

Download Data